HomeHealthcare & Life SciencesBiotechnology Peripheral Myelin Protein 22 Gene Related Disorder Market

North America Peripheral Myelin Protein 22 Gene Related Disorder Market Size & Outlook, 2026-2034


North America Peripheral Myelin Protein 22 Gene Related Disorder Market Insights

  • According to Reed Intelligence analysis, the North America Peripheral Myelin Protein 22 Gene Related Disorder Market size stood at USD 593.13 Million in 2025 and is forecasted to reach USD 1235.82 Million by 2034.
  • The market is projected to grow at a CAGR of 8.47% between 2026 and 2034.
  • By segment, Charcot-Marie-Tooth Disease Type 1A (CMT1A) was the leading Type in terms of market size in 2025.
  • Charcot-Marie-Tooth Disease Type 1A (CMT1A) is expected to be the most lucrative Type segment, exhibiting the fastest growth throughout the forecast period.

Other Key Findings


  • North America represented 37.54% of the global Peripheral Myelin Protein 22 Gene Related Disorder Market size in 2025.
  • By 2034, United States is estimated to hold the largest position in the global market in terms of size.
  • United States is estimated to remain the fastest-growing market in North America, advancing to USD 868.35 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 593.13 Million
Market Size In 2034 USD 1235.82 Million
Largest segment Charcot-Marie-Tooth Disease Type 1A (CMT1A)
Units Revenue in USD Million
CAGR 8.47% (2026-2034)
Segmnetation Covered
North America
  1. United States
  2. Canada
Type
  1. Charcot-Marie-Tooth Disease Type 1A (CMT1A)
  2. Hereditary Neuropathy with Liability to Pressure Palsies (HNPP)
Application
  1. Diagnostics
  2. Therapeutics
End-Use
  1. Hospitals and Clinics
  2. Research Institutes
  3. Diagnostic Laboratories
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports